Recent 8-K filings for MANE

• October 19, 2026, 9:06 AM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Veradermics VDPHL01 hits all Phase 3 '304' endpoints; TAHC up 28.6-36.4 hairs/cm² vs 6.6 placebo

  Study '304' randomized 536 males with mild-to-moderate pattern hair loss to VDPHL01 8.5mg once-daily, twice-daily or placebo; all primary and secondary endpoints met (p<0.0001).

• August 11, 2026, 8:15 AM ET earnings materiality 0.85 positive item 2.02item 9.01

  Veradermics Q2 net loss $23.5M; positive Phase 2 female hair-loss data, cash $819.9M

  Q2 2026 net loss $23.5M vs $15.6M YoY; R&D $18.6M (up $4.3M), G&A $10.9M (up $9.2M).

• July 15, 2026, 8:54 AM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Veradermics: Phase 2 VDPHL01 shows 22.7-23.3 hairs/cm² increase, 88.9-90% improved at Month 6

  Mean non-vellus hair count increase of 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily) at Month 6.

• May 12, 2026, 8:32 AM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Veradermics Q1 net loss $27.2M, positive Phase 2/3 results for VDPHL01 hair loss drug

  Net loss $27.2M for Q1 2026 vs $12.4M Q1 2025; R&D $20.9M, G&A $8.9M.

• May 1, 2026, 7:59 PM ET other material materiality 0.90 positive item 1.01item 3.02item 9.01 ◈ Equity Issuances◈ Material Agreements

  Veradermics raises $414M in public offering and private placement to Suvretta Capital

  Closed underwritten public offering of 3,843,790 shares at $100.00 per share, gross proceeds ~$384M.

• April 27, 2026, 7:59 PM ET other material materiality 0.95 positive item 7.01item 8.01item 9.01

  Veradermics' VDPHL01 meets all primary and key secondary endpoints in Phase 2/3 male hair loss trial

  VDPHL01 achieved mean TAHC increase of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID) vs 7.3 for placebo at Month 6 (p<0.0001)

• April 27, 2026, 7:59 PM ET earnings materiality 0.20 neutral item 2.02

  Veradermics reports preliminary cash of $390.8M as of March 31, 2026

  Preliminary unaudited cash, cash equivalents and marketable securities total approximately $390.8 million as of March 31, 2026.

• March 30, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Veradermics reports FY 2025 net loss $70M; cash $141.9M; IPO raised $295M; two pivotal trials enrolled

  FY 2025 net loss $70.0M vs $26.5M in 2024; Q4 net loss $21.8M vs $5.7M.

• February 5, 2026, 6:59 PM ET other materiality 0.50 neutral item 5.03item 9.01 ◈ Governance Changes ×2

  Veradermics files amended charter and bylaws after IPO closing on Feb 5, 2026

  Authorized 200M shares of common stock and 25M shares of undesignated preferred stock.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.85 · Most common event other_material

6 positive 0 negative 3 neutral

source · MANE on sec.gov